Win Medica launched a major collaboration with ACCORD Healthcare UK in May 2017. As part of this, it is strengthening its product portfolio by offering therapeutic solutions for patients with neoplastic diseases and hematological malignancies.
ACCORD Healthcare UK, one of the world’s fastest growing generics companies with a presence in over 60 countries, has received more than 5,500 formulation approvals. It has certified manufacturing plants by major organizations such as USFDA, UKMHRA, EMA, TGA, MCC, ANVISA. It also offers a complete and ever-expanding product portfolio across all therapeutic categories.
As its exclusive partner in Greece, Win Medica’s primary objective is to introduce an expanded product portfolio in Oncology and Hematology.
Win Medica is a Greek pharmaceutical company that has been active in the Greek market since 2008, aiming to improve the health and quality of life of patients and to save resources in the National Health System.
It offers a wide range of innovative and generic formulations for a number of serious diseases, while at the same time it covers the pharmacy sector through modern, reliable solutions for nutritional supplements and medical devices.
It operates in various therapeutic categories such as cardiology, metabolic diseases, diseases of the gastrointestinal system, etc.
Win Medica, true to its vision, approaches its goals through:
- Strategic alliances with leading research companies for the introduction and launch of novel formulations
- Presence in high value-added generic medicines
- Strategic positioning in the emerging markets of biosimilars, biotechnology products
- Expansion of its activities in the field of medical devices and nutritional supplements.
Mr. Marios Kosmidis, President and CEO of Win Medica, on the occasion of the ACCORD Healthcare UK collaboration, stated that “Cooperation with international and renowned groups is a strategic priority and a pillar of growth for Win Medica. The collaboration with ACCORD Healthcare UK, is a step of extroversion and enables the enrichment of our product portfolio, with full respect to the needs of patients with neoplastic diseases and hematological malignancies. We are particularly proud that bendamustine, a well-established drug with long-standing value in hematological malignancies, is becoming available to Greek patients for the first time. As such, it contributes fully to our goal of improving the health and quality of life of patients. We will continue to invest in patient-focused actions and partnerships, and provide excellent and affordable healthcare solutions for the healthcare system.”
Source : Mononews
